Venus Remedies has reported positive Top-Line results in its Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific meeting of the Infectious Diseases Society of America (IDSA).
The company’s four abstracts were accepted for poster presentations at the IDWeek 2018. These posters covered the efficacy results from the plea clinical trial, as well as supportive in vitro efficacy data from an AMR Surveillance study.
Venus Remedies is a pharmaceutical manufacturing company. The company is engaged in manufacturing products catering to various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties.